Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-dose ketamine injection for suicidal ideation in bipolar I depression
IRCT20141209020258N182Phase 3Completed
- Sponsor
- Arak University of Medical Sciences
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of ketamine in bipolar I disorder and suicidal ideation, sponsored by Arak University of Medical Sciences. Primary endpoint: Reduction in suicidal ideation. Started May 2023; status: completed.
02
Drugs
ketamine
03
Conditions
bipolar I disordersuicidal ideation
Beyond the preview
Go deeper on IRCT20141209020258N182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20141209020258N182.